// +author:d aubin +author:aubin 
var _ajax_res = {
  hits: 7,

  first: 0,

  results: [

{userid:"frauch", "refid":"306","repocollections":"","attachment":"","_thumb":"","articletype":"article","sectionheading":"","title":"Craniofacial and Dental Defects in the Col1a1Jrt\/+ Mouse Model of Osteogenesis Imperfecta.","year":"2016","author":"H Eimar, F Tamimi, J-M Retrouvey, F Rauch, J E Aubin, M D McKee","journal":"Journal of dental research","volume":"95","number":"7","pages":"761-768","month":"Jul","doi":"10.1177\/0022034516637045","pubmed":"26951553","pdflink":"","urllink":"","abstract":"Certain mutations in the COL1A1 and COL1A2 genes produce clinical symptoms of both osteogenesis imperfecta (OI) and Ehlers-Danlos syndrome (EDS) that include abnormal craniofacial growth, dental malocclusion, and dentinogenesis imperfecta. A mouse model (Col1a1(Jrt)\/+) was recently developed that had a skeletal phenotype and other features consistent with moderate-to-severe OI and also with EDS. The craniofacial phenotype of 4- and 20-wk-old Col1a1(Jrt)\/+ mice and wild-type littermates was assessed by micro-computed tomography (\u00b5CT) and morphometry. Teeth and the periodontal ligament compartment were analyzed by \u00b5CT, light microscopy\/histomorphometry, and electron microscopy. Over time, at 20 wk, Col1a1(Jrt)\/+ mice developed smaller heads, a shortened anterior cranial base, class III occlusion, and a mandibular side shift with shorter morphology in the masticatory region (maxilla and mandible). Col1a1(Jrt)\/+ mice also had changes in the periodontal compartment and abnormalities in the dentin matrix and mineralization. These findings validate Col1a1(Jrt)\/+ mice as a model for OI and EDS in humans.","note":"","tags":"Animals,Collagen Type I,Craniofacial Abnormalities,Disease Models, Animal,Ehlers-Danlos Syndrome,Mice,Mice, Mutant Strains,Microscopy,Microscopy, Electron,Osteogenesis Imperfecta,Periodontal Ligament,Tooth Abnormalities,X-Ray Microtomography","weight":306,"publisher":"","booktitle":"","editor":"","address":"","school":"","issn":"1544-0591","isi":"","key":"Eimar2016","howpublished":""}
,

{userid:"pccs", "refid":"39","repocollections":"","attachment":"","_thumb":"","articletype":"article","sectionheading":"","title":"Humpback whales Megaptera novaeangliae fatally poisoned by dinoflagellate toxin","year":"1989","author":"J R Geraci, D M Anderson, R J Timperi, D J St Aubin, G A Early, J H Prescott, C A Mayo*","journal":"Canadian Journal of Fisheries and Aquatic Sciences","volume":"46","number":"11","pages":"1895-1898","month":"","doi":"","pubmed":"","pdflink":"","urllink":"","abstract":"During a 5\u2013wk period beginning in late November, 1987, 14 humpback whales, Megaptera novaeangliae, died in Cape Cod Bay after eating Atlantic mackerel, Scomber scombrus, containing saxitoxin (STX), a dinoflagellate neurotoxin responsible for paralytic shellfish poisoning in humans. We propose a line of evidence to explain how whales, by virtue of their diving adaptations, may be particularly vulnerable to this systemic neurotoxin. Absence of STX in New England waters and shellfish during the episode suggests that the mackerel, representing the northern stock which spawns in the Gulf of St. Lawrence, accumulated the toxin there and delivered it to the Gulf of Maine and Cape Cod Bay in the fall of 1987. These findings challenge common perceptions of the manner in which planktonic toxins move through the food chain, and offer new insights into natural mortality and standings of marine mammals. It seems appropriate to search for STX and other phytotoxins when investigating marine mammal mortalities.","note":"","tags":"journal article, humpback whale","weight":"39","publisher":"","booktitle":"","editor":"","address":"","school":"","issn":"","isi":"","key":"ref77","howpublished":""}
,

{userid:"avollest", "refid":"12","attachment":"","_thumb":"","articletype":"article","sectionheading":"","title":"A critical review of adaptive genetic variation in Atlantic salmon : implications for conservation","year":"2007","author":"C Garcia de Leaniz, I A Fleming, S Einum, E Verspoor, W C Jordan, S Consuegra, N Aubin-Horth, D Lajus, B H Letcher, A F Youngson, J H Webb, L A V\u00f8llestad, B Villanueva, A Ferguson, T P Quinn","journal":"BIOLOGICAL REVIEWS","volume":"82","number":"2","pages":"173-211","month":"","doi":"10.1111\/j.1469-185X.2006.00004.x","pubmed":"","pdflink":"","urllink":"","abstract":"","note":"Times Cited: 34","tags":""}
,

{userid:"isabelle.borget", "articletype":"article","pages":"33-40","author":"M Kandel, C Allayous, S Dalle, L Mortier, S Dalac, C Dutriaux, M T Leccia, B Guillot, P Saiag, J P Lacour, D Legoupil, T Lesimple, F Aubin, M Beylot-Barry, F Brunet-Possenti, J P Arnault, F Granel-Brocard, P E Stoebner, A Dupuy, E Maubec, J J Grob, B Dreno, F Rotolo, A Ballon, S Michiels, C Lebbe, I Borget","year":"2018","title":"Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort.","month":"Dec","journal":"European journal of cancer (Oxford, England : 1990)","publisher":"","volume":"105","number":"","note":"","tags":"","booktitle":"","editor":"","abstract":"Since 2011, significant progress was observed in metastatic melanoma (MM), with the commercialisation of seven immunotherapies or targeted therapies, which showed significant improvement in survival. In France, in 2004, the cost of MM was estimated at \u20ac1634 per patient; this cost has not been re-estimated since. This study provided an update on survival and cost in real-life clinical practice.","address":"","school":"","issn":"1879-0852","doi":"10.1016\/j.ejca.2018.09.026","isi":"","pubmed":"30384014","key":"Kandel2018","howpublished":"","urllink":"","refid":4,"weight":4}
,

{userid:"stefan.michiels", "articletype":"article","pages":"33-40","author":"M Kandel, C Allayous, S Dalle, L Mortier, S Dalac, C Dutriaux, M T Leccia, B Guillot, P Saiag, J P Lacour, D Legoupil, T Lesimple, F Aubin, M Beylot-Barry, F Brunet-Possenti, J P Arnault, F Granel-Brocard, P E Stoebner, A Dupuy, E Maubec, J J Grob, B Dreno, F Rotolo, A Ballon, S Michiels, C Lebbe, I Borget","year":"2018","title":"Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort.","month":"12","journal":"European journal of cancer (Oxford, England : 1990)","publisher":"","volume":"105","number":"","note":"","tags":"Adult,Aged,Aged, 80 and over,Antineoplastic Agents,Cohort Studies,Cost-Benefit Analysis,Drug Costs,Female,France,Health Care Costs,Hospital Costs,Humans,Immunotherapy,Kaplan-Meier Estimate,Male,Melanoma,Middle Aged,Molecular Targeted Therapy,Prospective Studies,Survival Rate,Therapies, Investigational,Young Adult","booktitle":"","editor":"","abstract":"Since 2011, significant progress was observed in metastatic melanoma (MM), with the commercialisation of seven immunotherapies or targeted therapies, which showed significant improvement in survival. In France, in 2004, the cost of MM was estimated at \u20ac1634 per patient; this cost has not been re-estimated since. This study provided an update on survival and cost in real-life clinical practice.","address":"","school":"","issn":"1879-0852","doi":"10.1016\/j.ejca.2018.09.026","isi":"","pubmed":"30384014","key":"Kandel2018","howpublished":"","urllink":"","refid":"199","weight":"199"}
,

{userid:"federico.rotolo", "refid":33,"repocollections":"","attachment":"","_thumb":"","articletype":"article","sectionheading":"","title":"Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort","year":"2018","author":"M Kandel, C Allayous, S Dalle, L Mortier, S Dalac, C Dutriaux, MT Leccia, B Guillot, P Saiag, JP Lacour, D Legoupil, T Lesimple, F Aubin, M Beylot-Barry, F Brunet-Possenti, JP Arnault, F Granel-Brocard, PE Stoebner, A Dupuy, E Maubec, JJ Grob, B Dreno, F Rotolo, A Ballon, S Michiels, C Lebbe, I Borget","journal":"European Journal of Cancer","volume":"105","number":"","pages":"33-40","month":"","doi":"10.1016\/j.ejca.2018.09.026","pubmed":"30384014","pdflink":"","urllink":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959-8049(18)31396-0","abstract":"PURPOSE: Since 2011, significant progress was observed in metastatic melanoma (MM), with the commercialisation of seven immunotherapies or targeted therapies, which showed significant improvement in survival. In France, in 2004, the cost of MM was estimated at \u20ac1634 per patient; this cost has not been re-estimated since. This study provided an update on survival and cost in real-life clinical practice.\r\nMETHODS: Clinical and economic data (treatments, hospitalisations, radiotherapy sessions, visits, imaging and biological exams) were extracted from the prospective MelBase cohort, collecting individual data in 955 patients in 26 hospitals, from diagnosis of metastatic disease until death. Survival was estimated by the Kaplan-Meier method. Costs were calculated from the health insurance perspective using French tariffs. For live patients, survival and costs were extrapolated using a multistate model, describing the 5-year course of the disease according to patient prognostic factors and number of treatment lines.\r\nRESULTS: Since the availability of new drugs, the mean survival time of MM patients has increased to 23.6 months (95%confidence interval [CI] :21.2;26.6), with 58% of patients receiving a second line of treatment. Mean management costs increased to \u20ac269,682 (95%CI:244,196;304,916) per patient. Drugs accounted for 80% of the total cost.\r\nCONCLUSION: This study is the first that evaluated the impact of immunotherapies and targeted therapies both on survival and cost in real-life conditions. Alongside the introduction of breakthrough therapies in the first and subsequent lines, MM has been associated with a significant increase in survival but also in costs, raising the question of financial sustainability.","note":"","tags":"Metastatic melanoma, Cost, Survival, Real-life clinical practice, Immunotherapy, Targeted therapy","weight":33}
,

{userid:"stefan.michiels", "articletype":"article","pages":"","author":"N Jacquelot, M P Roberti, D P Enot, S Rusakiewicz, N Tern\u00e8s, S Jegou, D M Woods, A L Sodr\u00e9, M Hansen, Y Meirow, M Sade-Feldman, A Burra, S S Kwek, C Flament, M Messaoudene, C P M Duong, L Chen, B S Kwon, A C Anderson, V K Kuchroo, B Weide, F Aubin, C Borg, S Dalle, O Beatrix, M Ayyoub, B Balme, G Tomasic, A M Di Giacomo, M Maio, D Schadendorf, I Melero, B Dr\u00e9no, A Khammari, R Dummer, M Levesque, Y Koguchi, L Fong, M Lotem, M Baniyash, H Schmidt, I M Svane, G Kroemer, A Marabelle, S Michiels, A Cavalcanti, M J Smyth, J S Weber, A M Eggermont, L Zitvogel","year":"2017","title":"Predictors of responses to immune checkpoint blockade in advanced melanoma.","month":"09","journal":"Nature communications","publisher":"","volume":"8","number":"1","note":"","tags":"","booktitle":"","editor":"","abstract":"Immune checkpoint blockers (ICB) have become pivotal therapies in the clinical armamentarium against metastatic melanoma (MMel). Given the frequency of immune related adverse events and increasing use of ICB, predictors of response to CTLA-4 and\/or PD-1 blockade represent unmet clinical needs. Using a systems biology-based approach to an assessment of 779 paired blood and tumor markers in 37 stage III MMel patients, we analyzed association between blood immune parameters and the functional immune reactivity of tumor-infiltrating cells after ex vivo exposure to ICB. Based on this assay, we retrospectively observed, in eight cohorts enrolling 190 MMel patients treated with ipilimumab, that PD-L1 expression on peripheral T cells was prognostic on overall and progression-free survival. Moreover, detectable CD137 on circulating CD8+ T cells was associated with the disease-free status of resected stage III MMel patients after adjuvant ipilimumab\u2009+\u2009nivolumab (but not nivolumab alone). These biomarkers should be validated in prospective trials in MMel.The clinical management of metastatic melanoma requires predictors of the response to checkpoint blockade. Here, the authors use immunological assays to identify potential prognostic\/predictive biomarkers in circulating blood cells and in tumor-infiltrating lymphocytes from patients with resected stage III melanoma.","address":"","school":"","issn":"2041-1723","doi":"10.1038\/s41467-017-00608-2","isi":"","pubmed":"28928380","key":"Jacquelot2017","howpublished":"","urllink":"","refid":163,"weight":163}
  ]
}

;
ajaxResultsLoaded(_ajax_res);